The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study
Influenza may cause severe complications in patients with autoimmune inflammatory rheumatic disease (AIRD), to whom vaccinations are especially recommended. However, AIRD patients require cautious scrutiny of immunogenicity as they might exhibit poor antibody response to vaccination, especially when taking immunomodulatory medications.
The aim was to determine immunogenicity of seasonal and pandemic influenza vaccine in AIRD patients, its timeline/persistence, and influence of medications on immune response.
One hundred and thirty-seven AIRD and 54 healthy controls were vaccinated with trivalent seasonal influenza. After 3–5 weeks, 15 healthy controls and 93 AIRD were vaccinated with pandemic influenza vaccine, and 63 of patients were vaccinated a second time after 3–5 weeks. Sera were collected before vaccination, 18–90 days after each vaccination, and more than 180 days after the last vaccination. The immune response was measured using hemagglutination inhibition (HI) assay and IgG/IgA antibodies against influenza A/B with ELISA.
Our findings indicate that following vaccination with seasonal influenza vaccine, seroprotection, seroresponse, and change in geometric mean titers (GMT) in AIRD patients was not compromised compared to healthy. Similarly, we report for pandemic influenza vaccination little added benefit of the second dose. We confirm lowest increase in HI titer in rituximab-treated AIRD compared to other medications. Vaccination largely tilts the balance from negative ELISA A IgG and IgA titers to positive titers in seasonal H1N1 seroresponsive AIRD patients and controls. A significant decrease in HI GMT and seroprotection was observed only in AIRD at > 180 days after vaccination highlighting an absent persistence of immunogenic response in AIRD patients. Due to high initial HI titers for influenza vaccine, we foresee their benefit in personalized medicine in the future.
Influenza vaccination is immunologically active for AIRD, with little value of the second dose of the pandemic vaccine and further scrutiny on persistence of immune response to vaccine in AIRD is needed.
KeywordsAutoimmune inflammatory rheumatic disease Influenza Pandemic Seasonal Vaccination
Many thanks to the Blood Transfusion Centre of Slovenia for donating human 0 type erythrocytes for HI testing and WHO Collaborating Centre for Reference and Research on Influenza in London for providing the reference influenza viruses and antisera.
This work was funded by the Slovene Research Agency (ARRS) for the National Research Programme #P3-0314.
Compliance with ethical standards
Ethical approval for the study was obtained from the National Medical Ethics Committee of Slovenia (#122/09/09), and the study was conducted according to the principles outlined in the Declaration of Helsinki. All participants signed an informed consent.
- 1.PublicHealthAgencyofCanada (2016) Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2015–2016.. http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/flu-2015-grippe-eng.pdf. Accessed 1st July 2016
- 3.Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, D’Ancona F, Lévy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, O’Flanagan D (2014) Seasonal influenza immunisation in Europe. overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Eurosurveillance 19(16). https://doi.org/10.2807/1560-7917.ES2014.19.16.20780
- 5.Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P (2008) Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 26(1 Suppl 48):S67–S73Google Scholar
- 7.van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Muller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70(3):414–422. https://doi.org/10.1136/ard.2010.137216 CrossRefGoogle Scholar
- 8.Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H (2018) Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine 36(32 Pt B):4875–4879. https://doi.org/10.1016/j.vaccine.2018.06.065 CrossRefGoogle Scholar
- 9.Perdan-Pirkmajer K, Thallinger GG, Snoj N, Cucnik S, Zigon P, Kveder T, Logar D, Praprotnik S, Tomsic M, Sodin-Semrl S, Ambrozic A (2012) Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 21(2):175–183. https://doi.org/10.1177/0961203311429817 CrossRefGoogle Scholar
- 10.WHO (2009) Recommendations for influenza vaccine composition—Northern hemisphere: 2009–2010. http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index1.html. Accessed 15 Dec 2016
- 11.WHO (2009) Pandemic influenza A (H1N1) 2009 virus vaccine—conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. http://www.who.int/csr/disease/swineflu/meetings/sage_oct_2009/en/. Accessed 16 Dec 2016
- 13.SanofiPasteur (2009) VAXIGRIP inactivated influenza vaccine trivalent types A and B (Split Virion). SanofiPasteur. https://www.vch.ca/media/residential_0910_product_monograph_vaxigrip.pdf. Accessed 16 Dec 2016
- 14.EMA (2016) Pandemrix summary of product characteristics annex 1. http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121pdf Accessed 16 Dec 2016
- 16.Zambon M (1997) Laboratory diagnosis of influenza. In: Nicholson K, Webster R, Hay A (eds) Influenza. Blackwell, Oxford, pp 123–156Google Scholar
- 17.WHO (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Press. http://apps.who.int/iris/bitstream/10665/44518/1/9789241548090_eng.pdf. Accessed 27th July 2016
- 18.FDA (2007) Guidance for industry: clincal data needed to support the licensure of seasonal inactivated influenza vaccines. 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed 25th July 2016
- 19.EMA (2014) Guideline on influenza vaccines. Committee for Medicinal Products for Human Use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170300.pdf. Accessed 25 July 2016
- 21.ECDC (2011) Influenza surveillance in Europe 2010–2011. ECDC. http://ecdc.europa.eu/en/publications/Publications/111209_SUR_Influenza_surveillance_Europe%20_2010_2012.pdf. Accessed 16 Dec 2016
- 23.Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D (2010) The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 39(6):442–447. https://doi.org/10.1016/j.semarthrit.2008.12.002 CrossRefGoogle Scholar
- 26.Meroni PL, Zavaglia D, Girmenia C (2018) Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 36(2):317–328Google Scholar
- 28.Kobashigawa T, Nakajima A, Taniguchi A, Inoue E, Tanaka E, Momohara S, Yamanaka H (2013) Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 42(6):445–450. https://doi.org/10.3109/03009742.2013.788733 CrossRefGoogle Scholar
- 29.Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, Teufel A (1994) Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 21(7):1203–1206Google Scholar
- 30.Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713–716. https://doi.org/10.1136/ard.2007.077552 CrossRefGoogle Scholar
- 31.Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK (2014) Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 41(4):648–657. https://doi.org/10.3899/jrheum.130945 CrossRefGoogle Scholar
- 32.Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podesta E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Lagana B, DA R (2010) Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 134(2):113–120. https://doi.org/10.1016/j.clim.2009.09.014 CrossRefGoogle Scholar
- 33.Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M (2011) Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 63(7):1062–1067. https://doi.org/10.1002/acr.20465 CrossRefGoogle Scholar
- 34.Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, Moraes JC, Ribeiro AC, Viana VS, Pasoto SG, Carvalho JF, Franca IL, Guedes LK, Shinjo SK, Sampaio-Barros PD, Caleiro MT, Goncalves CR, Fuller R, Levy-Neto M, Timenetsky Mdo C, Precioso AR, Bonfa E (2011) Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 70(6):1068–1073. https://doi.org/10.1136/ard.2011.150250 CrossRefGoogle Scholar
- 35.Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA, Group HNS (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 63(6):1486–1496. https://doi.org/10.1002/art.30325 CrossRefGoogle Scholar
- 36.Iwamoto M, Homma S, Onishi S, Kamata Y, Nagatani K, Yamagata Z, Minota S (2012) Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 32(11):3691–3694. https://doi.org/10.1007/s00296-011-2118-1 CrossRefGoogle Scholar
- 38.van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75–81. https://doi.org/10.1002/art.25033 CrossRefGoogle Scholar
- 39.Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65(2):191–194. https://doi.org/10.1136/ard.2005.036434 CrossRefGoogle Scholar
- 42.Montomoli E, Capecchi B, Hoschler K (2011) Correlates of protection against influenza. Birkhauser Adv Infec:199–222. https://doi.org/10.1007/978-3-0346-0279-2_9
- 43.Jain VK, Bhashini N, Balajee LK, Sistla S, Parija SC, Negi VS (2017) Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis. Indian J Med Res 145(4):464–470. https://doi.org/10.4103/ijmr.IJMR_920_15
- 44.Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, Mori Y, Yamanishi K (2012) Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol: CVI 19(7):979–990. https://doi.org/10.1128/CVI.00016-12 CrossRefGoogle Scholar
- 45.Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN (2015) Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines. Clin Vaccine Immunol: CVI 22(7):679–687. https://doi.org/10.1128/CVI.00149-15 CrossRefGoogle Scholar
- 46.Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, Nguyen-Van-Tam JS, Abhishek A (2018) Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study. Rheumatology 57(10):1726–1734. https://doi.org/10.1093/rheumatology/key156 CrossRefGoogle Scholar